Can a new drug ease nerve pain in rare heart disease?
NCT ID NCT05023889
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug patisiran in 10 adults with a rare condition called ATTR amyloidosis that causes nerve damage. Participants received an IV infusion every 21 days for 24 months. Researchers measured changes in nerve function, autonomic symptoms, and quality of life to see if the drug could help control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- patisiran (also known as ONPATTRO)
- What this could lead to
- If successful, this could point toward a treatment that slows or improves nerve damage and quality of life in people with ATTR amyloidosis.
- What could go wrong
- This is a very small, early-phase study with only 10 participants, so results may not apply broadly. The drug also requires lifelong dosing and premedication, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYNEUROPATHIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Austin Neuromuscler Center/National Neuromuscular Research Institute
Austin, Texas, 78759, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Liver clues: a new way to stage heart amyloidosis?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can a daily pill keep a rare heart disease in check for the long haul?
- Gene Editing's lasting impact: a Long-Term look at NTLA-2001
- A muscle protein may signal nerve damage in diabetes — study puts it to the test
- Could your age change how a nerve test reads your nerves?